109 related articles for article (PubMed ID: 23039232)
21. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
22. Assessing the confidence level of public domain compound activity data and the impact of alternative potency measurements on SAR analysis.
Stumpfe D; Bajorath J
J Chem Inf Model; 2011 Dec; 51(12):3131-7. PubMed ID: 22059677
[TBL] [Abstract][Full Text] [Related]
23. Rationalizing three-dimensional activity landscapes and the influence of molecular representations on landscape topology and the formation of activity cliffs.
Peltason L; Iyer P; Bajorath J
J Chem Inf Model; 2010 Jun; 50(6):1021-33. PubMed ID: 20443603
[TBL] [Abstract][Full Text] [Related]
24. PSO-based multiobjective optimization with dynamic population size and adaptive local archives.
Leong WF; Yen GG
IEEE Trans Syst Man Cybern B Cybern; 2008 Oct; 38(5):1270-93. PubMed ID: 18784011
[TBL] [Abstract][Full Text] [Related]
25. Discovery of a new class of glucosylceramide synthase inhibitors.
Koltun E; Richards S; Chan V; Nachtigall J; Du H; Noson K; Galan A; Aay N; Hanel A; Harrison A; Zhang J; Won KA; Tam D; Qian F; Wang T; Finn P; Ogilvie K; Rosen J; Mohan R; Larson C; Lamb P; Nuss J; Kearney P
Bioorg Med Chem Lett; 2011 Nov; 21(22):6773-7. PubMed ID: 21974949
[TBL] [Abstract][Full Text] [Related]
26. Compound optimization through data set-dependent chemical transformations.
de la Vega de León A; Bajorath J
J Chem Inf Model; 2013 Jun; 53(6):1263-71. PubMed ID: 23654345
[TBL] [Abstract][Full Text] [Related]
27. Molecular similarity analysis uncovers heterogeneous structure-activity relationships and variable activity landscapes.
Peltason L; Bajorath J
Chem Biol; 2007 May; 14(5):489-97. PubMed ID: 17524980
[TBL] [Abstract][Full Text] [Related]
28. Structural interpretation of activity cliffs revealed by systematic analysis of structure-activity relationships in analog series.
Sisay MT; Peltason L; Bajorath J
J Chem Inf Model; 2009 Oct; 49(10):2179-89. PubMed ID: 19761254
[TBL] [Abstract][Full Text] [Related]
29. Novel hierarchical classification and visualization method for multiobjective optimization of drug properties: application to structure-activity relationship analysis of cytochrome P450 metabolism.
Yamashita F; Hara H; Ito T; Hashida M
J Chem Inf Model; 2008 Feb; 48(2):364-9. PubMed ID: 18211048
[TBL] [Abstract][Full Text] [Related]
30. From bird's eye views to molecular communities: two-layered visualization of structure-activity relationships in large compound data sets.
Kayastha S; Kunimoto R; Horvath D; Varnek A; Bajorath J
J Comput Aided Mol Des; 2017 Nov; 31(11):961-977. PubMed ID: 28986673
[TBL] [Abstract][Full Text] [Related]
31. Systematic assessment of compound series with SAR transfer potential.
Zhang B; Wassermann AM; Vogt M; Bajorath J
J Chem Inf Model; 2012 Dec; 52(12):3138-43. PubMed ID: 23186159
[TBL] [Abstract][Full Text] [Related]
32. Strength Pareto particle swarm optimization and hybrid EA-PSO for multi-objective optimization.
Elhossini A; Areibi S; Dony R
Evol Comput; 2010; 18(1):127-56. PubMed ID: 20064026
[TBL] [Abstract][Full Text] [Related]
33. SARANEA: a freely available program to mine structure-activity and structure-selectivity relationship information in compound data sets.
Lounkine E; Wawer M; Wassermann AM; Bajorath J
J Chem Inf Model; 2010 Jan; 50(1):68-78. PubMed ID: 20053000
[TBL] [Abstract][Full Text] [Related]
34. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
35. Optimization of molecular representativeness.
Yosipof A; Senderowitz H
J Chem Inf Model; 2014 Jun; 54(6):1567-77. PubMed ID: 24802762
[TBL] [Abstract][Full Text] [Related]
36. Analysis of a high-throughput screening data set using potency-scaled molecular similarity algorithms.
Vogt I; Bajorath J
J Chem Inf Model; 2007; 47(2):367-75. PubMed ID: 17300172
[TBL] [Abstract][Full Text] [Related]
37. Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors.
Park H; Kim SY; Kyung A; Yoon TS; Ryu SE; Jeong DG
Bioorg Med Chem Lett; 2012 Jan; 22(2):1271-5. PubMed ID: 22115589
[TBL] [Abstract][Full Text] [Related]
38. Identification of novel BRAF kinase inhibitors with structure-based virtual screening.
Park H; Choi H; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Oct; 21(19):5753-6. PubMed ID: 21873050
[TBL] [Abstract][Full Text] [Related]
39. Multiple Populations for Multiple Objectives: A Coevolutionary Technique for Solving Multiobjective Optimization Problems.
Zhan ZH; Li J; Cao J; Zhang J; Chung HS; Shi YH
IEEE Trans Cybern; 2013 Apr; 43(2):445-63. PubMed ID: 22907971
[TBL] [Abstract][Full Text] [Related]
40. Extraction of tacit knowledge from large ADME data sets via pairwise analysis.
Keefer CE; Chang G; Kauffman GW
Bioorg Med Chem; 2011 Jun; 19(12):3739-49. PubMed ID: 21616672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
